Bellicum Pharmaceuticals

173 articles about Bellicum Pharmaceuticals

• Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

  11/4/2021

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, reported financial results for the third quarter 2021 and provided an operational update.

• Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

  9/3/2021

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual).

• Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

  9/1/2021

  Bellicum Pharmaceuticals, Inc . and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe®

• Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update

  8/12/2021

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2021 and provided an operational update.

• Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 26, 2021

  7/26/2021

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options.

• Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

  6/28/2021

  Bellicum Pharmaceuticals, Inc. today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) and Massachusetts General Hospital (Mass General) covering certain intellectual property and technology rights regarding the company’s CaspaCIDe safety switch.

• Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

  5/17/2021

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update.

• Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

  3/30/2021

  Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the fourth quarter and full year 2020 and provided an operational update.

• Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate UpdateManagement to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT

  3/23/2021

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will report financial results for the fourth quarter and full year 2020 after the close of U.S. markets on Tuesday, March 30, 2021.

• Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

  3/4/2021

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch.

• Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

  1/28/2021

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer. Bellicum worked diligently with t

• Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

  12/10/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the Phase 1/2 clinical trial for BPX-603 in patients with tumors that express human epidermal growth factor 2 (HER2). BPX-603 is Bellicum’s first dual switch GoCAR-T ® product candidate that incorporates the company’s iMC activation and CaspaCIDe ® safety switc

• Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

  12/7/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been notified by the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase 1/2 dose-escalation clinical trial evaluating BPX-601 in patients with previously treated metastatic pancreatic or prostate cancer.

• Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update

  11/5/2020

  Strategic focus on clinical GoCAR-T® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

• Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

  11/4/2020

  Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock.

• 

  Beleaguered Bellicum Slashes 79% of Workforce in Restructuring

  10/30/2020

  Thursday afternoon, Bellicum announced it will pause the development of its BCMA GoCAR-NK program and will also discontinue discovery research and new product development.

• Bellicum Announces Interim BPX-601 Data and Corporate Restructuring

  10/29/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data from its BPX-601 dose-escalation clinical trial in patients with relapsed/refractory metastatic pancreatic cancer. Findings from the first four patients treated with BPX-601 followed by repeat rimiducid dosing showed evidence of rimiducid-mediated CAR-T cell activation. Clinically meaningful effica

• Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

  10/29/2020

  Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warran

• Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 30, 2020

  9/30/2020

  Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to one new employee consisting of an aggregate of 1,110 stock options.

• Bellicum to Participate in Two Upcoming Virtual Conferences

  9/28/2020

  Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual conferences. Conference Details: Jefferies Cell Therapy Virtual Summit Date/Time: Monday, October 5, 2020 at 11:30 a.m. EDT Format: Fireside chat 2020 Virtual Cell & Gene Meeting on the Mesa Date: Monday, October 12, 2020 – Friday, October